Section Arrow
Quote
ANIP.NASDAQ
- ANI Pharmaceuticals
Quotes are at least 15-min delayed:2026/05/15 11:19 EDT
Regular Hours
Last
 77.48
-2.1 (-2.64%)
Day High 
80 
Prev. Close
79.58 
1-M High
87.76 
Volume 
30.68K 
Bid
77.44
Ask
77.64
Day Low
77.45 
Open
79.28 
1-M Low
75.8797 
Market Cap 
1.81B 
Currency 美元 
P/E 19.8 
%Yield -- 
10-SMA 81.58 
20-SMA 80.54 
50-SMA 77.5 
52-W High 99.5 
52-W Low 56.71 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.91/9.48
Enterprise Value
2.41B
Balance Sheet
Book Value Per Share
24.73
Cash Flow
Cash Flow Yield
0.12
Income Statement
Total Revenue
883.37M
Operating Revenue Per Share
19.77
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health24.97+0.73+3.01%-- 
ESPREsperion Therapeutics3.125+0.005+0.16%-- 
CGCCanopy Growth Corp1.045-0.025-2.34%-- 
HLNHaleon plc8.915+0.005+0.06%18.07PE
TEVATeva Pharmaceutical Industries Limited33.875-1.435-4.06%25.28PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology,rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically,it generates maximum revenue from the United States, followed by other markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.